What the 2017 Seattle Verdict Against Olympus Actually Decided
The first U.S. trial over duodenoscope superbug outbreaks ended on July 24, 2017, with a mixed verdict that both sides described as a win. It is often summarized in one line, “$6.6 million against Olympus,” and that summary leaves out most of what the jury decided. This article explains the verdict, and what it can and cannot tell us about the lawsuits being filed today. It is general information, not legal advice.
The case
Theresa Bigler and her four children sued Olympus after the death of Richard Bigler in August 2013. Mr. Bigler, a pancreatic cancer patient, had contracted an infection linked to a contaminated Olympus scope at Virginia Mason Medical Center in Seattle. The hospital later joined the lawsuit against Olympus. The trial ran more than eight weeks.
Virginia Mason was the site of one of the largest outbreaks in the country. Infections in 39 patients were linked to Olympus scopes, and 18 of those patients died. The hospital said the patients who died, including Mr. Bigler, had other serious underlying illnesses.
What the jury decided
The jury made several separate findings:
- Warnings and instructions. The jury found that Olympus failed to provide adequate warnings about the scope, and adequate instructions for its use, after it was manufactured. It said that failure harmed the hospital.
- Design. The jury rejected the claim that the scope, the TJF-Q180V, was unsafe as designed.
- The hospital’s share. The jury also found the hospital negligent. It put the hospital’s damages at $25.4 million, then sharply reduced that figure to reflect the hospital’s own share of the blame. The result was an order for Olympus to pay the hospital $6.6 million.
- The family. The hospital was ordered to pay Mr. Bigler’s family $1 million.
Olympus said it appreciated the jury’s finding that the design was not unsafe. The family’s lawyer called the verdict a win for patient safety. Both statements were accurate descriptions of different parts of the same result.
Design defect and failure to warn are different claims
Product liability lawsuits commonly rest on one or more legal theories. Two of the most common are a design defect, meaning the product is unreasonably dangerous as designed, and a failure to warn, meaning the manufacturer did not give adequate warnings or instructions. A third, a manufacturing defect, concerns a particular unit that departs from its intended design. A jury can accept one theory and reject another, which is what happened here. The rules differ from state to state, and a lawyer reviewing a particular case decides which theories fit its facts.
What this verdict does not tell us
- It is one jury’s decision on one set of facts. It does not bind other courts or juries.
- It concerned an older model. The trial involved the TJF-Q180V. Olympus recalled all 4,400 of those duodenoscopes in 2016 and made repairs to reduce the risk of trapped bacteria. Newer lawsuits involve other models. A wrongful death suit filed in federal court in Washington state this year, for example, alleges an infection from a TJF-Q190V.
- It was not a ruling on today’s scopes or on the lawsuits now being filed. Each case turns on its own evidence.
What came after
In December 2018, Olympus Medical Systems and a former senior executive pleaded guilty to failing to file required adverse event reports with the FDA. The reports concerned infections in Europe linked to the TJF-Q180V in 2012 and 2013. Olympus paid $85 million in fines and forfeiture. That criminal case was separate from the Seattle civil trial. For the broader history, see our litigation timeline.
Why it matters if you are considering a claim
The Seattle verdict is a reminder that these cases are not all alike. Which scope was used, what procedure was performed, which infection developed and when, and what the facility did all matter. Claims may rest on a failure to warn as well as on design, and time limits for filing differ by state. A free, confidential case review is the way to find out how those factors apply to your situation.
Sources
- KFF Health News: Scope Maker Olympus Hit With $6.6 Million Verdict In Superbug Outbreak Case (July 2017)
- Fierce Healthcare: Jury orders Olympus to pay $6.6M in damages to Virginia Mason Medical Center for scope-linked superbug outbreak
- News-Medical: Scope maker Olympus hit with $6.6 million verdict in superbug outbreak case (July 25, 2017)
- U.S. Department of Justice: Olympus Medical Systems Corporation, Former Senior Executive Plead Guilty to Distributing Endoscopes After Failing to File FDA-Required Adverse Event Reports of Serious Infections (December 10, 2018)
- Infection Control Today: Can Reusable Duodenoscopes Still Transmit Infections? New Olympus Lawsuit Alleges Fatal VRE Case (July 2026)
Facts in this article come from the sources listed above and were current when the article was published or last updated. Statements about lawsuits describe allegations, which are claims and not findings by a court.
This article is general information, not medical or legal advice. Reading it does not create an attorney-client relationship. If you have symptoms of an infection, contact your health care provider. Attorney advertising. Prior results do not guarantee a similar outcome.